SlateStone Wealth’s Erin Gibbs joined CNBC’s Worldwide Exchange to explain why easing inflation and renewed confidence in Fed rate cuts are creating a favorable setup for small- and mid-cap stocks, which she notes offer lower valuations and stronger expected profit growth heading into 2026. She also highlighted improving momentum in biotech approvals and pointed to Neurocrine Biosciences as a well-positioned name with strong cash flow and late-stage catalysts.
Watch the full segment here.